Sumitomo Pharma Co., Ltd.
SMDPY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $398,832,000 | $314,558,000 | $555,544,000 | $560,035,000 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Cost of Goods Sold | $153,437,000 | $126,577,000 | $178,919,000 | $157,127,000 |
| Gross Profit | $245,395,000 | $187,981,000 | $376,625,000 | $402,908,000 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| R&D Expenses | $49,865,000 | $112,637,000 | $131,858,000 | $94,903,000 |
| G&A Expenses | $180,605,000 | $429,538,000 | $279,355,000 | $179,559,000 |
| SG&A Expenses | $180,605,000 | $429,538,000 | $339,212,000 | $217,339,000 |
| Sales & Mktg Exp. | $0 | $0 | $59,857,000 | $37,780,000 |
| Other Operating Expenses | -$13,879,000 | $0 | -$17,466,000 | $30,432,000 |
| Operating Expenses | $216,591,000 | $542,175,000 | $453,604,000 | $342,674,000 |
| Operating Income | $28,804,000 | -$354,194,000 | -$76,979,000 | $60,234,000 |
| % Margin | 7.2% | -112.6% | -13.9% | 10.8% |
| Other Income/Exp. Net | -$11,193,000 | $31,745,000 | $29,059,000 | $22,727,000 |
| Pre-Tax Income | $17,611,000 | -$323,114,000 | -$47,920,000 | $82,961,000 |
| Tax Expense | -$6,024,000 | -$8,185,000 | $48,794,000 | $42,361,000 |
| Net Income | $23,634,000 | -$314,969,000 | -$74,512,000 | $56,413,000 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| Weighted Avg Shares Out | 397,290 | 397,292 | 397,292 | 397,293 |
| Weighted Avg Shares Out Dil | 397,290 | 397,292 | 397,292 | 397,293 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,307,000 | $36,022,000 | $32,218,000 | $25,777,000 |
| Interest Expense | $13,500,000 | $4,277,000 | $3,159,000 | $3,050,000 |
| Depreciation & Amortization | $25,562,000 | $37,765,000 | $41,263,000 | $38,348,000 |
| EBITDA | $56,673,000 | -$281,072,000 | -$3,498,000 | $124,359,000 |
| % Margin | 14.2% | -89.4% | -0.6% | 22.2% |